BioMarin Pharmaceutical Inc.
BMRNHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeHeadquartered within the healthcare sector, BioMarin Pharmaceutical Inc. focuses on Biotechnology services and products. BioMarin Pharmaceutical Inc., a biotechnology company, engages in the development and commercialization of therapies for life-threatening rare diseases and medical conditions in the United States,. The $10.31B market capitalization puts BMRN squarely in large-cap range for its industry. The company's products include VIMIZIM, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; VOXZOGO, a once daily injection analog of c-type natriuretic peptide (CNP) for the treatment of achondroplasia; NAGLAZYME, a recombinant form of N- acetylgalactosamine 4-sulfatase for patients with MPS VI; and PALYNZIQ, a PEGylated recombinant phenylalanine (Phe) ammonia lyase enzyme delivered through subcutaneous injection to reduce blood Phe concentrations.
Market Cap
$10.31B
Beta
0.23
P/E (TTM)
38.36
P/E (Fwd)
8.25
EPS (TTM)
$1.39
EPS (Fwd)
$6.46
ROE
4.5%
ROA
4.5%
Cash
$2.22B
Total Debt
$1.44B
Free CF
$459.4M
52W Change
-5.0%
Annual Financials
Cash vs Debt
The balance sheet looks solid with $2.22B in cash comfortably exceeding the $1.44B debt load. A net cash position generally provides financial flexibility during uncertain economic periods. The company generates $459.4M in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing. ROE of 4.5% points to modest capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. ROA of 4.5% is on the lower side, which is common in asset-heavy industries. Revenue has grown from $2.10B (2022) to $3.22B (2025), reflecting a 54% increase over the period.
With a beta below 0.7, BioMarin Pharmaceutical Inc. typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for BioMarin Pharmaceutical Inc. and its sector.